A Phage’s “Loose Cannon”: How One Enzyme Disarms Bacterial Immunity

The bacteriophage T7, a virus that infects Escherichia coli, has long been a workhorse of molecular biology, yet a study published in August 2026 in Nature reveals that one of its enzymes conceals a genuinely novel strategy for defeating its host’s defenses. Researchers at the European Molecular Biology Laboratory in Heidelberg have discovered that a viral kinase named T7K, first identified nearly five decades ago, phosphorylates almost the entire proteome of the infected bacterium within minutes, a phenomenon so indiscriminate that the investigators nicknamed the enzyme a molecular “loose cannon.”

Employing modern phosphoproteomics, the team detected close to twenty thousand phosphorylated peptides during wild-type infection, a scale exceeding the combined output attributed to the roughly five hundred kinases encoded by the human genome. Crucially, this hyperactivity is not entirely random: a DNA-binding domain at the enzyme’s carboxy-terminal end steers its otherwise promiscuous catalytic activity toward proteins that interact with nucleic acids, precisely the class of molecules that many bacterial immune systems rely upon to sense viral DNA. Phosphorylation of specific residues within two defense modules, Retron-Eco9 and DarTG1, was sufficient to abolish their protective function, as single phosphomimetic mutations at these sites eliminated bacterial resistance to infection.

Screening a panel of more than five hundred naturally occurring Escherichia coli isolates further showed that this anti-defense mechanism operates broadly in nature, weakening resistance in strains carrying diverse, often unidentified immune systems, and homologous kinases were found conserved across an entire family of related phages. Structural modeling suggests that an unusual amino-acid motif locks the enzyme’s active site permanently open, a molecular trick that may explain its extraordinary catalytic promiscuity.

The findings carry real significance for phage therapy, an approach gaining ground as antibiotic resistance narrows conventional options: phages engineered with broadly acting anti-defense enzymes like T7K could help overcome the varied immune arsenals of clinical bacterial pathogens. The evidence so far comes mainly from laboratory Escherichia coli strains, and how phosphorylation biochemically inactivates several of the newly implicated defense proteins remains unclear. Whether similarly promiscuous kinases operate in phages infecting other therapeutically relevant bacterial genera is an open question — one this study’s methodology actively invites other laboratories to pursue. Even so, the work reframes a nearly fifty-year-old enzymatic curiosity as a paradigm for how post-translational modification can disable molecular machinery on a proteome-wide scale.